Aclaris Therapeutics, Inc. 8-K

What Happened Aclaris Therapeutics, Inc. filed an 8-K (Regulation FD disclosure) reporting that between March 2 and March 9, 2026 the company sold 12.7 million shares of its common stock for aggregate gross proceeds of $39.8 million. The sales were made pursuant to the company’s amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co., dated February 27, 2025. The Agents informed Aclaris that the shares were purchased by institutional investors, including Deep Track Capital.

Key Details

• 12.7 million shares sold from March 2–9, 2026.
• Aggregate gross proceeds: $39.8 million.
• Sales made under the amended and restated sales agreement dated February 27, 2025, with Leerink Partners LLC and Cantor Fitzgerald & Co.
• Buyers identified by the Agents include institutional investors such as Deep Track Capital.

Why It Matters This transaction raises near-term capital for Aclaris, increasing the company’s cash resources by roughly $39.8 million before fees and expenses. For existing shareholders, issuance of 12.7 million new shares is dilutionary and will increase the company’s shares outstanding. Investors should monitor Aclaris’s public disclosures for any statements about intended use of proceeds or additional financings.